AbbVie releases phase 3 induction therapy data on injectable Skyrizi for Crohn's
FROM THE WIRE · SEEKINGALPHA.COM
AbbVie’s phase 3 AFFIRM data show subcutaneous Skyrizi improved Crohn’s endoscopic remission and ulcer-free rates. Read more here.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive phase 3 data support Skyrizi's efficacy profile and could strengthen the drug's commercial potential.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Subcutaneous Skyrizi improved endoscopic remission and ulcer-free rates in Crohn's disease.
- 02Phase 3 AFFIRM data represent an important milestone in the drug's clinical development.
- 03Positive results could support future regulatory approvals and indication expansion.